Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 13, 2026, 4:25 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2953–2976 of 85,971 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: 1 Clear all

Conditions: Multiple Myeloma
Interventions: Clarithromycin, Lenalidomide, Dexamethasone; Drug
Lead sponsor: Weill Medical College of Cornell University; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2020
U.S. locations: 1
States / cities: New York, New York

Conditions: Prostate Cancer
Interventions: Intratumoral (IT) Poly ICLC 0.5 mg, Intratumoral (IT) Poly ICLC 1.0 mg, Intramuscular (IM) Poly ICLC, Radical Prostatectomy; Biological · Procedure
Lead sponsor: Ashutosh Kumar Tewari; Other
Eligibility: 18 Years and older · Male only
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 1
States / cities: New York, New York

Conditions: Hyponatremia, Inappropriate ADH Syndrome
Interventions: Urea; Drug
Lead sponsor: Helbert Rondon Berrios, MD, MS; Other
Eligibility: 18 Years and older
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Metastatic Head and Neck Squamous Cell Carcinoma, Advanced Malignancies, Recurrent Head and Neck Squamous Cell Carcinoma
Interventions: INCAGN01876, retifanlimab; Biological
Lead sponsor: Incyte Biosciences International Sàrl; Industry
Eligibility: 18 Years to 99 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 17
States / cities: Birmingham, Alabama • La Jolla, California • Palo Alto, California + 14 more

Conditions: Child Obesity
Interventions: Four FOP label designs; Other
Lead sponsor: Michigan State University; Other
Eligibility: 6 Years to 10 Years
Enrollment: 80 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016
U.S. locations: 1
States / cities: East Lansing, Michigan

Conditions: Lymphoma, Non-Hodgkin
Interventions: recombinant human interleukin 21 and rituximab; Drug
Lead sponsor: ZymoGenetics; Industry
Eligibility: 18 Years and older
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: COVID19, ARDS
Interventions: CK0802, Placebo; Biological · Drug
Lead sponsor: Cellenkos, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 5
States / cities: Baltimore, Maryland • New York, New York • Chapel Hill, North Carolina + 2 more

Conditions: Hepatic Impairment, Liver Disease, Pharmacokinetics
Interventions: Elafibranor; Drug
Lead sponsor: Genfit; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 2
States / cities: Miami, Florida

Conditions: Ependymoma, Anaplastic Ependymoma
Interventions: Carboplatin, Bevacizumab; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2021
U.S. locations: 2
States / cities: Boston, Massachusetts • New York, New York

Conditions: Pancreatic Cancer, Cancer of the Pancreas
Interventions: huCART-meso cells; Biological
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years and older
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2025
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Tear Trough Hollowing, Under Eye Bags
Interventions: Hyaluronic Acid Filler and Platelet Rich Fibrin (PRF), Hyaluronic Acid Filler and Saline; Combination Product
Lead sponsor: Rejuva Medical Aesthetics; Other
Eligibility: 20 Years to 80 Years
Enrollment: 10 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Benign Prostatic Hyperplasia
Interventions: placebo, sildenafil; Drug
Lead sponsor: Pfizer's Upjohn has merged with Mylan to form Viatris Inc.; Industry
Eligibility: 35 Years to 75 Years · Male only
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2003
U.S. locations: 2
States / cities: Laguna Woods, California • Newport Beach, California

Conditions: Delayed Onset Muscle Soreness, DOMS
Interventions: SST-0225, Placebo; Drug
Lead sponsor: Strategic Science & Technologies, LLC; Industry
Eligibility: 16 Years to 65 Years
Enrollment: 156 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2016
U.S. locations: 3
States / cities: Hollywood, Florida • South Miami, Florida • Springfield, Missouri

Conditions: Advanced Cancer
Interventions: Donepezil, Placebo; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2007
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Breast Cancer, Fatigue, Insomnia
Interventions: Therapeutic Massage; Procedure
Lead sponsor: Floyd Memorial Hospital and Health Services; Other
Eligibility: 18 Years and older · Female only
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: New Albany, Indiana

Conditions: Rheumatoid Arthritis
Interventions: Diet 1, Diet 2; Other
Lead sponsor: University of California, San Diego; Other
Eligibility: 18 Years and older
Enrollment: 124 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 1
States / cities: La Jolla, California

Conditions: Sjögren-Larsson Syndrome
Interventions: Active topical NS2 1% dermatologic cream, Vehicle placebo 0.0% NS2 dermatologic cream; Drug
Lead sponsor: Aldeyra Therapeutics, Inc.; Industry
Eligibility: 6 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 3
States / cities: Omaha, Nebraska • Hershey, Pennsylvania • Fairfax, Virginia

Conditions: Migraine
Interventions: Frovatriptan, Placebo; Drug
Lead sponsor: Thomas Jefferson University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 74 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Lymphedema
Interventions: Pycnogenol, Placebo; Drug
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 18 Years and older · Female only
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2007
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Pain, Inflammation
Interventions: Restorative-Flow Yoga; Behavioral
Lead sponsor: Weill Medical College of Cornell University; Other
Eligibility: 60 Years and older · Female only
Enrollment: 38 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Ithaca, New York

Conditions: Metastatic Pancreatic Adenocarcinoma
Interventions: Ibrutinib, Paclitaxel, Gemcitabine; Drug
Lead sponsor: Margaret Tempero; Other
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2020
U.S. locations: 2
States / cities: San Francisco, California • Portland, Oregon

Conditions: Anaplastic Large Cell Lymphoma, Nodal Peripheral T-Cell Lymphoma With TFH Phenotype, Recurrent Anaplastic Large Cell Lymphoma, Recurrent Angioimmunoblastic T-Cell Lymphoma, Recurrent Enteropathy-Associated T-Cell Lymphoma, Recurrent Follicular Lymphoma, Recurrent Hepatosplenic T-Cell Lymphoma, Recurrent Mature T- Cell and NK-Cell Non-Hodgkin Lymphoma, Recurrent Monomorphic Epitheliotropic Intestinal T-cell Lymphoma, Recurrent Mycosis Fungoides, Recurrent Peripheral T-Cell Lymphoma, Not Otherwise Specified, Refractory Anaplastic Large Cell Lymphoma, Refractory Angioimmunoblastic T-Cell Lymphoma, Refractory Enteropathy-Associated T-Cell Lymphoma, Refractory Follicular Lymphoma, Refractory Hepatosplenic T-Cell Lymphoma, Refractory Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma, Refractory Mycosis Fungoides, Refractory Peripheral T-Cell Lymphoma, Not Otherwise Specified, Subcutaneous Panniculitis-Like T-Cell Lymphoma
Interventions: Pembrolizumab, Pralatrexate; Biological · Drug
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2027
U.S. locations: 3
States / cities: Duarte, California • Atlanta, Georgia • Omaha, Nebraska

Conditions: Influenza
Interventions: NanoFlu, Fluzone HD - Day 0, Fluzone HD - Day 21, Saline - Day 21; Biological · Other
Lead sponsor: Novavax; Industry
Eligibility: 60 Years and older
Enrollment: 330 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 3
States / cities: Raleigh, North Carolina • Rocky Mount, North Carolina • Statesville, North Carolina

Conditions: Brain Cancer
Interventions: TPI 287; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: Houston, Texas

Search by objective public record fields.

Phase II Study of Biaxin, Revlimid, and Dexamethasone for Untreated Multiple Myeloma

Neoadjuvant Hiltonol® (PolyICLC) for Prostate Cancer

Urea for Chronic Hyponatremia

INCAGN01876 in Combination With Immunotherapy in Participants With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

Using Video Gaming to Evaluate Front of Pack Labeling With Children

Study of Recombinant Interleukin 21 in Combination With Rituxan for Non-Hodgkin's Lymphoma

REgulatory T Cell infuSion fOr Lung Injury Due to COVID-19 PnEumonia

Elafibranor Pharmacokinetic Parameters in Hepatic Impaired Patients

Carboplatin and Bevacizumab for Recurrent Ependymoma

CAR T Cell Immunotherapy for Pancreatic Cancer

Platelet Rich Fibrin for Tear Trough Rejuvenation

A Study to Investigate the Effects on Blood Pressure and Pulse Rate of a Single 100mg Dose of Sildenafil in Patients With Benign Prostatic Hyperplasia Who Are Being Treated With Doxazosin

Study of SST-0225 Topical Ibuprofen Cream in the Treatment of Delayed Onset Muscle Soreness (DOMS)

The Effect of Donepezil on Sedation and Other Symptoms

The Clinical and Biochemical Effect of Therapeutic Massage on Fatigue and Insomnia in Women With Breast Cancer Receiving Radiation Therapy

Effect of Anti-inflammatory Diet in Rheumatoid Arthritis

A Study of Topical NS2 Cream to Treat Ichthyosis in Sjögren-Larsson Syndrome (SLS)

A Research Study To Evaluate If Frovatriptan Is Safe And Effective In Preventing Migraine Headache After Fasting

Pycnogenol for the Treatment of Lymphedema

Flow-Restorative Yoga to Decrease Pain and Inflammation

Ibrutinib Combined With Gemcitabine and Nab-Paclitaxel in Patients With Metastatic Pancreatic Cancer

Pembrolizumab and Pralatrexate in Treating Patients With Relapsed or Refractory Peripheral T-Cell Lymphomas

Evaluation of the Safety and Immunogenicity of a Recombinant Trivalent Nanoparticle Influenza Vaccine With Matrix M-1 Adjuvant (NanoFlu)

TPI 287 in Patients With Recurrent Glioblastoma Multiforme